Streetbeat News

Price Targets

BMY

Morgan Stanley analyst Terence Flynn has reiterated an 'Underweight' rating on Bristol-Myers Squibb (BMY) and maintained a price target of $59.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:04 pm

BLUE

Morgan Stanley analyst Matthew Harrison has reiterated an 'Underweight' rating on bluebird bio (NASDAQ:BLUE) and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:03 pm

BNTX

Morgan Stanley analyst Matthew Korn has maintained an Equal-Weight rating on BioNTech (NASDAQ:BNTX) but lowered the price target from $124 to $119.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:02 pm

GNRC

Argus Research analyst John Eade has upgraded Generac Hldgs (NYSE:GNRC) from Hold to Buy and set a price target of $155.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 1:00 pm

BIIB

Morgan Stanley analyst Matthew Harrison has maintained an Overweight rating on Biogen (NASDAQ:BIIB) but lowered the price target from $371 to $355.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:58 pm

FOLD

Morgan Stanley analyst Andrew Galler has reiterated an Equal-Weight rating on Amicus Therapeutics (NASDAQ:FOLD) and maintained a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:57 pm

AES

Barclays analyst Stephen Byrd has maintained an Overweight rating on AES (NYSE:AES) but lowered the price target from $31 to $29.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:54 pm

ADCT

Morgan Stanley analyst Matthew Harrison has reiterated an Equal-Weight rating on ADC Therapeutics (NYSE:ADCT) and maintained a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:50 pm

ACAD

Morgan Stanley analyst Jeffrey Hung has maintained an Equal-Weight rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and raised the price target from $20 to $21.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:48 pm

ABBV

Morgan Stanley analyst Terence Flynn has reiterated an Overweight rating on AbbVie (NYSE:ABBV) and maintained a price target of $182.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:46 pm